Loading...
•
Jun 30, 2024
The Joint Q2 2024 Earnings Report
The Joint Corp. Q2 2024 financial results were reported, with revenue growing 3%, system-wide sales increasing 8%, and system-wide comp sales up 2% compared to Q2 2023.
Key Takeaways
The Joint Corp. reported a 3% increase in revenue to $30.3 million for Q2 2024. System-wide sales increased by 8% to $129.6 million, and system-wide comp sales grew by 2%. The company reported a net loss of $3.6 million, including $1.5 million in litigation expense and $1.4 million in loss on disposition or impairment. Adjusted EBITDA was $2.1 million.
Revenue grew 3% to $30.3 million compared to Q2 2023.
System-wide sales increased 8% to $129.6 million.
System-wide comp sales increased 2%.
The total clinic count reached 960 at June 30, 2024.
Forward Guidance
The company reiterated all elements of its guidance.
Positive Outlook
- System-wide sales are expected to be between $530 and $545 million, compared to $488.0 million in 2023.
- System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.
- New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...